araag2/HINT huggingface dataset:
Clinical trial NCT00516828 (phase 1/phase 2, status: completed)
Conditions: leukemia, myelodysplastic syndromes
ICD codes: C95.91, C95.92, Z80.6, Z85.6, C90.11, C90.12, C91.01, D46.9, D46.C, D46.Z
Drugs: cytarabine
SMILES: ClCCN(CCCl)P1(=O)NCCCO1
Eligibility criteria:

        DISEASE CHARACTERISTICS:

          -  Diagnosis of 1 of the following:

               -  Acute myeloid leukemia (AML) by FAB criteria (By morphology and routine
                  histochemistry and confirmed, when possible, by flow cytometric analysis of
                  surface immunophenotype; co-expression of lymphoid markers permitted)

               -  High-risk myelodysplastic syndromes defined as IPSS category of intermediate-2 or
                  greater

          -  Must be considered unsuitable for intensive chemotherapy regimens

          -  No documented CNS involvement

        PATIENT CHARACTERISTICS:

          -  ECOG performance status 0-2

          -  AST and ALT ≤ 2 times upper limit of normal (ULN)

          -  Bilirubin normal

          -  Creatinine ≤ 1.2 times ULN OR creatinine clearance ≥ 50 mL/min

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception

          -  No history of other malignancies, except adequately treated nonmelanoma skin cancer,
             curatively treated in situ carcinoma of the cervix, or other solid tumors curatively
             treated with no evidence of disease for ≥ 5 years

          -  No upper gastrointestinal or other conditions that would preclude compliance with or
             administration of oral medication

          -  No serious illness or medical condition that would not permit the patient to be
             managed according to the protocol, including any of the following:

               -  History of significant neurologic or psychiatric disorder that would impair the
                  ability to obtain consent

               -  Active, uncontrolled, serious infections

               -  Active peptic ulcer disease

               -  Evidence of bleeding diathesis

          -  No myocardial infarction within the past 6 months

          -  No congestive heart failure

          -  No unstable angina

          -  No active cardiomyopathy or unstable ventricular arrhythmia

          -  No poorly controlled hypertension (e.g., systolic BP ≥ 150 mm Hg or diastolic BP ≥ 95
             mm Hg)

          -  No known hypersensitivity to the study drugs or their components

          -  No preexisting hypothyroidism prior to enrollment unless patient is euthyroid on
             medication

          -  No neuropathy ≥ grade 2

        PRIOR CONCURRENT THERAPY:

          -  At least 2 days since prior hydroxyurea

          -  No other prior chemotherapy

          -  No concurrent therapeutic doses (≥ 2 mg/day) of anticoagulants (e.g., warfarin)

               -  Doses of up to 2 mg/day given for prophylaxis of thrombosis are accepted provided
                  INR is ≤ 1.5

          -  No other concurrent experimental drugs or anticancer therapy
Clinical trial NCT00470847 (phase 1, status: completed)
Conditions: breast cancer, brain metastases
ICD codes: C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, D48.60
Drugs: lapatinib, herceptin
SMILES: CN(C1=CC2=NN(C)C(C)=C2C=C1)C1=CC=NC(NC2=CC=C(C)C(=C2)S(N)(=O)=O)=N1
Eligibility criteria:

        Inclusion Criteria:

          -  Histologically or cytologically-confirmed invasive breast cancer

          -  HER2 overexpressing breast cancer defined as 3+ staining by immunohistochemistry, or
             HER2 gene amplification by FISH

          -  At least one parenchymal brain metastasis

          -  Disease progression in the CNS as assessed by at least one of the following; new
             neurological signs or symptoms; new lesion(s) in the CNS on an imaging study;
             progressive lesions on an imaging study

          -  At least two weeks since prior radiotherapy, last chemotherapy, immunotherapy,
             biologic therapy, or major surgery for cancer

          -  18 years of age or older

          -  Life expectancy of greater than 12 weeks

          -  ECOG performance status 0-2

          -  Normal organ and marrow function as described in the protocol

          -  Left ventricular ejection fraction > 50%

          -  Able to swallow and retain oral medications

        Exclusion Criteria:

          -  Prior WBRT

          -  Receiving any other investigational agents

          -  Concurrent chemotherapy, immunotherapy, biologic therapy or hormonal therapy for
             treatment of their cancer

          -  History of grade 3 or 4 allergic reactions attributed to compounds of similar chemical
             or biologic composition to herceptin or lapatinib

          -  Leptomeningeal carcinomatosis as the only site of CNS involvement

          -  Concurrent treatment with medications that are either inducers of inhibitors of CYP3A4

          -  Malabsorption syndrome, disease significantly affecting gastrointestinal function, or
             resection of the stomach or small bowel or active ulcerative colitis

          -  History of immediate or delayed hypersensitivity reaction to gadolinium contrast
             agents

          -  Other known contraindication to MRI

          -  Uncontrolled intercurrent illness

          -  History of other active malignancy except curatively treated basal cell carcinoma or
             squamous cell carcinoma of the skin, or carcinoma in situ of the cervix

          -  Pregnant or breastfeeding women
Clinical trial NCT02720120 (phase 1/phase 2, status: terminated)
Conditions: rheumatoid arthritis
ICD codes: M06.9, M05.9, M06.08, M06.00, M06.011, M06.012, M06.019
Drugs: ocrelizumab, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Reason stopped: 
    the overall benefit risk profile of ocrelizumab was not favorable in ra
  
Eligibility criteria:

        Inclusion Criteria:

          -  Moderate to severe RA for at least 6 months

          -  Positive serum rheumatoid factor (>/= 20 international units per milliliter)

          -  Current treatment with RA on an outpatient basis

          -  Treatment failure with one disease modifying anti-rheumatic drug (DMARD) or biologic,
             but have not failed more than six of these agents including methotrexate

          -  Current treatment with methotrexate for at least 12 weeks, at a stable dose

          -  Use of highly effective contraception.

        Exclusion Criteria:

          -  Rheumatic autoimmune disease or inflammatory joint disease, other than RA

          -  Concurrent treatment with any disease-modifying anti-rheumatic drug (DMARD) (other
             than methotrexate) or any anti-tumor necrosis factor (TNF) -alfa or other biologic
             therapy

          -  Treatment with any other investigational drug within 4 weeks of screening

          -  Previous treatment with cell-depleting therapies, IV gamma-globulin, intra-articular
             or parenteral corticosteroids, and receipt of live/attenuated vaccine prior to
             screening

          -  Previous treatment with rituximab or any other anti-cluster of differentiation 20
             (CD20) agent

          -  History of severe allergic or anaphylactic reactions to humanized monoclonal
             antibodies

          -  Known active bacterial, viral or fungal infections

          -  History of active tuberculosis and primary or secondary immunodeficiency

          -  History of concomitant diseases such as cardiovascular disease, nervous system,
             pulmonary disease, renal, hepatic, endocrine or gastrointestinal disorders

          -  Pregnancy or lactation.
Clinical trial NCT01023230 (phase 1, status: completed)
Conditions: hepatitis b, chronic
ICD codes: B18.0, B18.1, B18.2, B18.8, B18.9
Drugs: dv-601, entecavir
SMILES: CCOC(=O)C1=CC=C(N)C=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Male and female subjects 18 to 65 years of age.

          -  Signed informed consent.

          -  Diagnosis of CHB and candidates for therapy

          -  Normal renal function

          -  Women of childbearing potential must have a serum negative pregnancy test at
             screening. Women of childbearing potential and males whose sexual partners are of
             childbearing potential must agree to use dual methods of contraception.

        Exclusion Criteria:

          -  Liver disease other than CHB

          -  Documented co-infection with hepatitis A virus (HAV), hepatitis C virus (HCV), or HIV

          -  Previous therapy with interferon alpha.

          -  Any other antiviral therapy for chronic hepatitis B within the previous 3 months prior
             to Screening Visit.

          -  Immunosuppressive treatment (e.g. chemotherapy, high-dose of steroids) within 6 months
             of Screening Visit.

          -  Evidence of cirrhosis

          -  Child-Turcotte-Pugh (CTP) score ≥ 7, either currently or at any occasion in the past

          -  Clinically significant acute or chronic illnesses, such as autoimmune diseases,
             collagen vascular disease, immune deficiencies, active or uncontrolled infections,
             etc. as determined by the investigator and documented in medical history.

          -  Malignancy other than curatively treated, superficial skin cancer or carcinoma in situ
             of the cervix.

          -  Participation in any experimental protocol or therapy within 28 days prior to the
             Screening Visit.

          -  Current substance or alcohol abuse that in the opinion of the investigator would
             interfere with compliance or with interpretation of study results.
Clinical trial NCT00553969 (phase 1/phase 2, status: completed)
Conditions: pre-hypertension
ICD codes: O11.1, O11.2, O11.3, O11.4, O11.9, O11.5, O10.02
Drugs: carvedilol phosphate, lisinopril, carvedilol phosphate and lisinopril, placebo and placebo
SMILES: COC1=CC=CC=C1OCCNCC(O)COC1=CC=CC2=C1C1=CC=CC=C1N2, CC(C)NCC(O)COC1=CC=C(CC(N)=O)C=C1, COC1=CC=CC=C1OCCNCC(O)COC1=CC=CC2=C1C1=CC=CC=C1N2, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Males and females > 18 years old with pre-hypertensive or borderline blood pressures
             (systolic blood pressure ≥ 130 mmHg or diastolic blood pressure ≥ 85 mmHg) deemed not
             to need antihypertensive therapy. Subjects must also have one additional risk factor
             for cardiovascular disease, including:

          -  LDL > 130 and < 160 mg/dL

          -  HDL < 40 mg/dL

          -  Fasting blood sugar >100 and < 126 mg/dL

          -  Body mass index ≥ 30

          -  Smoker

          -  Family history of premature heart disease or hypertension

        Exclusion Criteria:

          -  Patients with a history of cardiac, cerebral or other vascular events within the
             previous 6 months will be excluded. Other exclusions include background therapy with a
             beta blocker or ACE inhibitor therapy, known or suspected intolerance to beta blockers
             or ACE inhibitors, angiotensin receptor blocker therapy, or diabetes. Pregnant or
             lactating women, and women of child-bearing age who are not using an acceptable form
             of contraception are also excluded from this study.
Clinical trial NCT01703312 (phase 1/phase 2, status: completed)
Conditions: allergic asthma
ICD codes: D69.0, L50.0, B44.81, J30.89, J30.9, L20.84, H10.45
Drugs: qge031, omalizumab, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

        Adult patients 18 to 65 years

        Positive skin prick test to one or more common airborne allergens

        Presence of airway hyperresponsiveness documented by a provocative concentration of
        methacholine causing a 20% fall in FEV1 (PC20 FEV1) of less than or equal to 16 mg/mL

        Presence of an early asthmatic response demonstrated by an allergen challenge at screening
        and including a 15% fall in the FEV1

        Patients with a body weight and total IgE in a range specified by local country prescribing
        information for omalizumab

        Exclusion Criteria:

        Pregnant or nursing (lactating) women

        Women of child-bearing potential unless they are using a highly effective method of birth
        control (as further defined in the study protocol)

        Smokers

        Patients with poorly controlled asthma or patients who have had an asthma exacerbation
        within the past year

        Other protocol-defined inclusion/exclusion criteria may apply.
Clinical trial NCT01746901 (phase 1, status: completed)
Conditions: healthy
ICD codes: Z76.3, Z76.2
Drugs: placebo, intact alo-02 60 mg/7.2 mg, crushed alo-02 60 mg/7.2 mg, crushed oxycodone ir 60 mg, crushed alo-02 40 mg/4.8 mg, crushed oxycodone ir 40 mg
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CC(=O)OC1=CC=CC=C1C(O)=O, CC(=O)OC1=CC=CC=C1C(O)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Healthy subjects.

          -  Non-dependent, recreational opioid users. (Must use opioid for non-therapeutic
             purposes on at least 10 occassions within the last year before Screening Visit, and at
             least once in 8 weeks before the Screening Visit.

        Exclusion Criteria:

          -  Diagnosis of substance and/or alcohol dependence.

          -  Subject has participated in, is currently participating in, or is seeking treatment
             for substance and/or alcohol related disorder.

          -  History of sleep apnea.

          -  Positive urine drug screen (UDS) for other that marijuana.

          -  Positive for Hepatitis B or C and HIV on Screening.
Clinical trial NCT01098838 (phase 1, status: completed)
Conditions: advanced solid tumors
ICD codes: K74.02, G47.22, H35.3133, H35.3134, H35.3113, H35.3114, H35.3123
Drugs: lcl161
SMILES: CN[C@@H](C)C(=O)N[C@@H](C1CCCCC1)C(=O)N1CCC[C@H]1C1=NC(=CS1)C(=O)C1=CC=C(F)C=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Solid tumor

          -  ECOG performance status 0-2

          -  Life expectancy greater than or equal to 12 weeks

          -  Must meet certain blood laboratory values

          -  Must meet criteria for time since the last dose of prior therapy

          -  Must provide written informed consent to participate in this study

        Exclusion Criteria:

          -  Active and/or symptomatic brain tumors or brain metastases.

          -  Patients with unresolved nausea, vomiting, or diarrhea

          -  Any ongoing severe and/or uncontrolled medical condition that could compromise
             participation in the study including heart, lung or inflammatory disease

          -  Any disease that may significantly alter the absorption of the study drug (for
             example, ulcerative diseases, uncontrolled nausea, vomiting, diarrhea, malabsorption
             syndrome, or removal of small bowel)

          -  Patients who are currently receiving treatment with steroids at a certain dose or
             other immunosuppressive treatment that cannot be stopped prior to starting study drug

          -  Patients who are currently receiving treatment with certain medications

          -  Patients who have received radiation therapy or have undergone major surgery within
             the last 4 weeks

          -  Women of child-bearing potential who are pregnant or breast feeding.

          -  Known diagnosis of human immunodeficiency virus (HIV) infection or chronic active
             hepatitis B or C

          -  Patients unwilling or unable to follow the protocol

        Other protocol-defined inclusion/exclusion criteria may apply
Clinical trial NCT00705315 (phase 1/phase 2, status: completed)
Conditions: breast cancer
ICD codes: C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, D48.60
Drugs: docetaxel, epirubicin, bevacizumab
SMILES: [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, CN(C1=CC2=NN(C)C(C)=C2C=C1)C1=CC=NC(NC2=CC=C(C)C(=C2)S(N)(=O)=O)=N1, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1
Eligibility criteria:

        Inclusion Criteria:

          -  Histologically- or cytologically- confirmed metastatic breast adenocarcinoma

          -  No HER2 overexpression or gene amplification

          -  No previous therapy for metastatic breast cancer is allowed

          -  Age 18-75 years

          -  At least 12 months interval since prior adjuvant therapy with taxanes and/or
             anthracyclines

          -  Measurable disease as defined by the presence of at least one measurable lesion
             (except bone metastases, ascites or pleural effusions)

          -  Performance status (WHO) 0-2

          -  Adequate liver (serum bilirubin <1.5 times the upper normal limit, AST and ALT <2.5
             times the upper normal limit in the absence of demonstrable liver metastases, or <5
             times the UNL in the presence of liver metastases)

          -  Adequate renal function (serum creatinine <1.5 times the upper normal limit

          -  Adequate bone marrow function (neutrophils ≥ 1.5x 109 /L, and platelets ≥ 100x 109 /L)

          -  Written informed consent

        Exclusion Criteria:

          -  Active infection

          -  Brain metastases

          -  History of significant cardiac disease (unstable angina, congestive heart failure,
             myocardial infarction within the previous 6 months, ventricular arrhythmias)

          -  History of stroke

          -  Anticoagulation therapy (except of low dose aspirin <325mg)

          -  Other invasive malignancy except nonmelanoma skin cancer

          -  Psychiatric illness or social situation that would preclude study compliance

          -  Pregnant or lactating women
Clinical trial NCT01069757 (phase 1, status: completed)
Conditions: non-small-cell lung cancer
ICD codes: C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, C34.2
Drugs: arq 197 and erlotinib
SMILES: O=C1NC(=O)[C@H]([C@@H]1C1=CNC2=CC=CC=C12)C1=CN2CCCC3=C2C1=CC=C3
Eligibility criteria:

        Inclusion Criteria:

          -  Voluntary written informed consent for study participation must be obtained

          -  A histologically or cytologically confirmed advanced/recurrent non-small-cell lung
             cancer

          -  History of ≥1 prior chemotherapy regimen (treatment with EGFR tyrosine kinase
             inhibitors will be counted as one regimen)

          -  ECOG PS of 0 or 1

          -  Life expectancy of ≥3 months

        Exclusion Criteria:

          -  Anti-cancer chemotherapy, anti-cancer therapy with EGFR-TKI, hormone therapy,
             radiotherapy, immunotherapy, other investigational agents or anti-cancer antibody
             therapy within 28 days prior to ARQ 197 dose

          -  Surgery for cancer within 28 days prior to ARQ 197 dose

          -  Active double cancer

          -  Known symptomatic brain metastases

          -  An intercurrent illness that is uncontrolled (e.g., infection, symptomatic congestive
             heart failure, unstable angina pectoris, symptomatic arrhythmia, interstitial
             pneumonia)

          -  Pregnant or lactating

          -  Subjects who wish to have a child and who would not agree to use contraceptive
             measures
Clinical trial NCT00472849 (phase 1/phase 2, status: completed)
Conditions: richter's transformation, leukemia
ICD codes: C95.91, C95.92, Z80.6, Z85.6, C90.11, C90.12, C91.01
Drugs: oxaliplatin, fludarabine, cytarabine, rituximab, pegfilgrastim
SMILES: [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, ClCCN(CCCl)P1(=O)NCCCO1, ClCCN(CCCl)P1(=O)NCCCO1, ClCCN(CCCl)P1(=O)NCCCO1, CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)[C@H](CO)C1=CC=CC=C1
Eligibility criteria:

        Inclusion Criteria:

          -  All patients with histologically or cytologically confirmed Richter's transformation,
             prolymphocytic leukemia, aggressive, or relapsed/refractory B-cell chronic lymphocytic
             leukemia are eligible for this protocol.

          -  Patients must be 18 years of age or older.

          -  Patients must have a performance status of 0-2 (Zubrod scale).

          -  Patients must have adequate renal function (serum creatinine <= 2 mg/dL or creatinine
             clearance > 50 mL/min). Patients with renal dysfunction due to organ infiltration by
             disease may be eligible after discussion with the principal investigator (PI) and
             consideration of appropriate dose adjustments.

          -  Patients must have adequate hepatic function (bilirubin <= 2 mg/dl; aspartate
             aminotransferase (AST or SGOT) and alanine aminotransferase (ALT or SGPT) < 2.5 * the
             upper limit of normal (ULN) for the reference lab unless due to leukemia or congenital
             hemolytic disorder [for bilirubin]). Patients with hepatic dysfunction due to organ
             infiltration by disease may be eligible after discussion with the PI and consideration
             of appropriate dose adjustments.

          -  Female patients of childbearing potential (including those < 1 year post-menopausal)
             and male patients must agree to use contraception.

          -  Patients must sign an informed consent indicating that they are aware of the
             investigational nature of this study.

          -  Patients must have platelet counts > 20,000, unless lower counts are due to disease
             involvement or autoimmune disorders.

        Exclusion Criteria:

          -  Untreated or uncontrolled life-threatening infection.

          -  Oxaliplatin, fludarabine, cytarabine or rituximab intolerance.

          -  Pregnancy or lactation.

          -  Chemotherapy and/or radiation therapy within 4 weeks.

          -  Medical condition, including mental illness or substance abuse, deemed by the
             investigator to be likely to interfere with a patient's ability to sign informed
             consent, cooperate and participate in the study, or interfere with the interpretation
             of the results.
Clinical trial NCT00551564 (phase 1, status: completed)
Conditions: diabetes mellitus, type 2
ICD codes: E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: rosiglitazone maleate
SMILES: CCN1C=C(C(O)=O)C(=O)C2=C1C=C(C=C2)C1=CC=NC=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Male and/or females aged 18-65 years

          -  Females must either be of non-childbearing potential or childbearing potential (but
             not pregnant) and using appropriate methods of contraception.

          -  Healthy normal or overweight control subjects or healthy obese subjects or subjects
             with T2DM.

        Exclusion Criteria:

          -  Clinically significant past or current medical conditions

          -  Clinically significant abnormalities in vital signs or routine laboratory parameters